Loading patent…
AssigneeThe Board of Regents of the University of Oklahoma
InventorPaul L. DeAngelis
Estimating the term…
The presently claimed and disclosed invention relates, in general, to dual action heparin synthases and, more particularly, to dual action heparin synthases obtained from Pasteurella multocida. The presently claimed and disclosed invention also relates to heparosan, heparin and heparin-like molecules provided by recombinant techniques and methods of using such molecules and also the identification or prediction of heparin synthases or component single action enzymes. The presently claimed and disclosed invention also relates to methods, and molecules produced according to such methods, for using the presently claimed and disclosed heparosan and/or heparin synthase for polymer grafting and the production of non-naturally occurring chimeric polymers incorporating stretches of one or more acidic GAG molecules, such as heparin, chondroitin, hyaluronan, and/or heparosan.
A purified nucleic acid segment comprising a coding region encoding enzymatically active heparin synthase, wherein the heparin synthase is a single protein that is a dual-action catalyst that utilizes UDP-GlcUA and UDP-GlcNAc to synthesize heparin, and wherein the purified nucleic acid segment is selected at least one of:
A recombinant vector selected from the group consisting of a plasmid, cosmid, phage, integrated cassette and virus vector, wherein the recombinant vector comprises:
A recombinant host cell, wherein the recombinant host cell is a electroporated, transformed, transfected, or transduced to introduce a recombinant vector into the host cell, wherein the recombinant vector comprises:
A method for producing a heparin polymer in vitro, comprising the steps of:
A method for producing a heparin polymer in vivo, comprising the steps of:
Dependencies are inferred from the claim text.